Free Newsletter
FDA mulls behind-the-counter drug sales
Once, the gap between prescription drugs and over-the-counter sales was a wide No Man's Land where few products roamed. Now, the FDA may settle more medications in this country, known as behind-the-counter (BTC) sales, in part to improve access for the uninsured.
The agency is seeking public comment on the potential move, which would allow patients to buy certain remedies after consultation with a pharmacist. Though the FDA won't cite specific meds that might be included, experts cite birth control pills and cholesterol-lowering remedies as possibilities.
- see the AP article
Related Articles:
House overhauls, passes PDUFA. Report
FDA clears Plan B, ending FDA confirmation fight. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: